scholarly journals Calcitonin Response to Naturally Occurring Ionized Hypercalcemia in Cats with Chronic Kidney Disease

2018 ◽  
Vol 32 (2) ◽  
pp. 727-735
Author(s):  
D.H.N. van den Broek ◽  
R.F. Geddes ◽  
T.L. Williams ◽  
Y.-M. Chang ◽  
J. Elliott ◽  
...  
2020 ◽  
Vol 34 (4) ◽  
pp. 1476-1487
Author(s):  
Bianca N. Lourenço ◽  
Amanda E. Coleman ◽  
Jaime L. Tarigo ◽  
Roy D. Berghaus ◽  
Cathy A. Brown ◽  
...  

2008 ◽  
Vol 22 (5) ◽  
pp. 1111-1117 ◽  
Author(s):  
L.M. Boyd ◽  
C. Langston ◽  
K. Thompson ◽  
K. Zivin ◽  
M. Imanishi

PLoS ONE ◽  
2014 ◽  
Vol 9 (10) ◽  
pp. e110057 ◽  
Author(s):  
Anna Shipov ◽  
Gilad Segev ◽  
Hagar Meltzer ◽  
Moran Milrad ◽  
Ori Brenner ◽  
...  

2019 ◽  
Vol 20 (15) ◽  
pp. 3668 ◽  
Author(s):  
Elena Oliva-Damaso ◽  
Nestor Oliva-Damaso ◽  
Francisco Rodriguez-Esparragon ◽  
Juan Payan ◽  
Eduardo Baamonde-Laborda ◽  
...  

Asymmetric dimethylarginine (ADMA) and its enantiomer, Symmetric dimethylarginine (SDMA), are naturally occurring amino acids that were first isolated and characterized in human urine in 1970. ADMA is the most potent endogenous inhibitor of nitric oxide synthase (NOS), with higher levels in patients with end-stage renal disease (ESRD). ADMA has shown to be a significant predictor of cardiovascular outcome and mortality among dialysis patients. On the other hand, although initially SDMA was thought to be an innocuous molecule, we now know that it is an outstanding marker of renal function both in human and in animal models, with ESRD patients on dialysis showing the highest SDMA levels. Today, we know that ADMA and SDMA are not only uremic toxins but also independent risk markers for mortality and cardiovascular disease (CVD). In this review, we summarize the role of both ADMA and SDMA in chronic kidney disease along with other cardiovascular risk factors.


2017 ◽  
Vol 18 (7) ◽  
pp. 1481 ◽  
Author(s):  
Lorenzo Signorini ◽  
Simona Granata ◽  
Antonio Lupo ◽  
Gianluigi Zaza

Sign in / Sign up

Export Citation Format

Share Document